SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies.

Ölmestig, JNE; Marlet, IR; Hainsworth, AH; Kruuse, C (2017) Phosphodiesterase 5 inhibition as a therapeutic target for ischemic stroke: A systematic review of preclinical studies. Cell Signal, 38. pp. 39-48. ISSN 1873-3913 https://doi.org/10.1016/j.cellsig.2017.06.015
SGUL Authors: Hainsworth, Atticus Henry

[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (860kB) | Preview

Abstract

Phosphodiesterase 5 inhibitors (PDE5i), such as sildenafil (Viagra®) are widely used for erectile dysfunction and pulmonary hypertension. Preclinical studies suggest that PDE5i may improve functional outcome following ischemic stroke. In this systematic review we aimed to evaluate the effects of selective PDE5i in animal models of brain ischaemia. A systematic search in Medline, Embase, and The Cochrane Library was performed including studies in English assessing the effects of selective PDE5i. 32 publications were included describing outcome in 3646 animals. Neuroprotective effects of PDE5i were dependent on the NO-cGMP-PKG-pathway. These included reduced neuronal apoptosis (n=3 studies), oxidative stress (n=5), and neuroinflammation (n=2). PDE5i increased angiogenesis and elevated regional cerebral blood flow in the ischemic penumbra, and improved functional recovery. Some studies found that PDE5i treatment reduced lesion volume (n=9), others found no effect (n=9). Treatment was effective when administered within 24h post-ischemia, though treatment delayed to seven days improved outcome in one study. This review demonstrates both neuroprotective and neurorestorative effects of PDE5i in animal models of stroke, though the specific underlying signaling pathways relating to PDE5 inhibition and cGMP may remain serendipitous in some studies. There is currently limited evidence on the effects of selective PDE5i in human stroke patients, hence translation of preclinical results into clinical trials may be warranted.

Item Type: Article
Additional Information: © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: PDE5 inhibitor, Phosphodiesterase 5 inhibitor, cerebrovascular disorder, stroke translational models, PDE5 inhibitor, Phosphodiesterase 5 inhibitor, cerebrovascular disorder, stroke translational models, Biochemistry & Molecular Biology, 0601 Biochemistry And Cell Biology
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Cell Signal
ISSN: 1873-3913
Language: eng
Dates:
DateEvent
October 2017Published
21 June 2017Published Online
2 June 2017Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDAlzheimer Societyhttp://dx.doi.org/10.13039/501100000143
20140901Alzheimer Drug Discovery Foundationhttp://dx.doi.org/10.13039/100002565
PubMed ID: 28648945
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108998
Publisher's version: https://doi.org/10.1016/j.cellsig.2017.06.015

Actions (login required)

Edit Item Edit Item